You must be signed in to use this feature.


Pinedo Prize Awardees

The following distinguished physician-scientists have earned the prestigious Pinedo Cancer Care Prize.

2015 Award: Richard M. Goldberg,
The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Professor Richard M. Goldberg, is recognized for his clinical and research leadership in gastrointestinal cancers, coupled with his compassionate care of cancer patients.

A respected expert in colorectal cancer, Dr. Goldberg has led a national intergroup study N9741 as part of an international phase III study of oxaliplatin, irinotecan and 5-fluorouracil in combinations for first-line treatment of advanced colorectal cancer. This study, which resulted in approval of oxaliplatin for clinical use, was conducted in centers across the United States and Canada. It helped change the standard of care for patients with advanced colorectal cancer.

The 2015 Pinedo Prize was presented at the STO Fifth Annual meeting, hosted by OSUCCC – James at the Biomedical Research Tower (BRT) in Columbus, Ohio on April 10-11, 2015. Prof. Goldberg delivered the keynote lecture "Integrating Pathologic and Genomic Factors to Make Treatment Decisions in Patients with GI Cancers" at the meeting which will be published by The Oncologist, STO's official journal.
Video available online.


2013 Award: Patrick G. Johnston,
Queen's University Belfast

Professor Patrick G. Johnston is recognized for his pioneering work in translating discovery science for the benefit of cancer patients. His determination and leadership in establishing a Comprehensive Cancer Care and Research Program in Northern Ireland is testament to his dedication to improving both clinical outcomes and quality of life for cancer patients.

Prof. Johnston's research has focused on understanding the cellular signaling pathways in gastrointestinal tumors (with a particular emphasis on colorectal cancer) and using this information as a foundation to identify novel prognostics and diagnostic biomarkers, and molecular targets to rationalize and improve patient care. His many significant papers on both cytotoxic and targeted therapies have expanded knowledge of the treatment of colorectal cancer and provided new insights on mechanisms of drug resistance.

The 2013 Pinedo Prize of $50,000 was presented at the 4th Annual Meeting of the Society for Translational Oncology, hosted by the VU University Medical Center Cancer Center Amsterdam (VUmc CCA) in Amsterdam, The Netherlands. Prof. Johnston delivered the keynote lecture "Identification of Clinically Relevant Molecular Subtypes in Colorectal Cancer: The Dawning of a New Era" at the meeting which was published by The Oncologist, STO's official journal.
Video available online.


2012 Award: Richard L. Schilsky,
The University of Chicago Department of Medicine

Professor Schilsky is recognized for his clinical and research leadership in the areas of gastrointestinal cancers and cancer pharmacology, coupled with his compassionate care of cancer patients. An internationally recognized expert on gastrointestinal malignancies, he is also a leader in the development and evaluation of new treatments for cancer. He is past Chairman of the Cancer and Leukemia Group B, a national cancer clinical trials group sponsored by the National Cancer Institute, and a former chair of the Board of Scientific Advisors of the National Cancer Institute and of the Oncology Drugs Advisory Committee of FDA. A past president of the American Society of Clinical Oncology, he was recently named an ASCO fellow.

Professor Schilsky was awarded the 2012 Pinedo Care Cancer Prize at the STO 3rd Annual Meeting, held October 20-21, 2012, in Chapel Hill, North Carolina. His keynote lecture, "Publicly Funded Clinical Trials and the Future of Cancer Care," was published in The Oncologist, STO's official journal, and can be read here.


2011 Award: Gabriel N. Hortobágyi,
The University of Texas MD Anderson Cancer Center

Professor Hortobágyi is widely recognized for developing combined modality therapy for previously inoperable breast tumors, improving multidisciplinary treatment for patients with all stages of the disease and conducting clinical trials to develop treatment regimens that have become standard practices for managing breast cancer. A past president of ASCO, he is on the Board of Directors of the Conquer Cancer Foundation and has previously held leadership positions with Susan G. Komen for the Cure and the International Association of Breast Cancer Research. He has been recognized for his groundbreaking research efforts with many awards, including honorary doctorates from 3 leading universities in Italy, Mexico and Argentina.

Professor Hortobágyi was awarded the 2011 Pinedo Cancer Care Prize at the STO meeting in Belfast, Northern Ireland on September 7, 2011. He presented the keynote lecture "Towards Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside" which can be read here.


2010 Award: José Baselga,
Memorial Sloan Kettering Cancer Center

Professor Baselga relocated from Barcelona, Spain in the summer of 2010 to become chief of the Division of Hematology/Oncology and associate director of the Mass General Cancer Center. He has made seminal advances in breast cancer research, developing new, targeted cancer-fighting agents.  Prof. Baselga was chairman of the Medical Oncology Service and founder and director of the Division of Medical Oncology, Hematology and Radiation Oncology at the Vall d'Hebron Institute of Oncology, Barcelona, Spain. He was a professor of medicine at the Universidad Autonoma de Barcelona. A recipient of many distinguished awards, Prof. Baselgaalso received from Queen Sofia of Spain the coveted Echevarne Foundation National Prize in Oncology, one of Spain's highest honors.


2009 Award: Richard J. O'Reilly,
Memorial Sloan Kettering Cancer Center

Professor O'Reilly is known for pioneering bone marrow transplantation research spanning more than three decades.  He started the clinical and preclinical research program in Memorial Sloan-Kettering Cancer Center in New York and established a worldwide reputation for bone marrow transplantations of children with severe combined immune deficiencies and leukemias.  He is Chair of Sloan-Kettering's department of pediatrics and Chief of the pediatric bone marrow transplant service.


2008 Award: Bob Löwenberg,
Erasmus Medical Center, Rotterdam

Professor Löwenberg is Professor of Hematology and since 1990 has been Department Chair at Erasmus University Medical Center in Rotterdam, the Netherlands.  Prof. Löwenberg's research activities are in the treatment and the pathobiology of leukemia, lymphoma and stem cell transplantation.  He is extensively published in the area of development diagnostics and therapeutics in leading scientific journals.  ProfLöwenberg is on the editorial board of several international journals.  He was one of the founders and has served as President of the European Haematology Association (EHA). He has also served as president of the International Society of Experimental Hematology and the International Society of Hematology. In 2011, he was appointed editor of Blood.


2007 Award: Joseph R. Bertino,
New Jersey Cancer Center

Professor Bertino has been internationally recognized for his role in finding curative treatments for leukemia and lymphoma. He is University Professor of medicine and pharmacology, UMDNJ-Robert Wood Johnson Medical School and is the interim director of the school's Cancer Institute of New Jersey in New Brunswick. He was named interim director of the Stem Cell Institute of New Jersey in 2007. He has been an American Cancer Society professor since 1976. Prof. Bertino joined The Cancer Institute of New Jersey in 2002 as associate director and was appointed chief scientific officer in 2004.


Bruce Chabner

2006 Inaugural Award: Bruce A. Chabner,
Massachusetts General Hospital Cancer Center

Professor Chabner, an internationally renowned oncologist and cancer pharmacologist, has devoted both his clinical and research careers to the improvement of patient treatment and care affecting patients throughout the world. One of the unique and very important features of Dr. Chabner's career has been his continued focus on the improvement of treatments for patients, and to this day this remains his major goal.  His work has led to significant advances in the quality of care provided to patients. During his tenure at the NCI and Harvard Medical School, he has been involved in leading therapeutic advance such as high-dose therapies as well as targeted therapies for lymphoma, colorectal cancer and breast cancer.